Generated by AI
Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead product, Rezdiffra, is a once-daily oral therapy designed to address the underlying biology of MASH in adults with moderate to advanced liver fibrosis. The company’s current business is centered on liver disease, with a commercial presence supported by medical affairs, patient support, and market access activities. Madrigal Pharmaceuticals Inc. also maintains research and clinical development efforts around thyroid hormone receptor-beta science, reinforcing its role as a specialist company in hepatology and metabolic medicine. Based in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals Inc. serves a focused segment of the biopharmaceutical market that targets chronic liver and metabolic disorders.
Website1001 Conshohocken State Road
West Conshohocken, PA, 19428
United States
The latest articles about MDGL.
Summary of Nov 10's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Summary of Dec 22's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Investors talking about MDGL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.